Codivir trial for hospitalized moderate COVID-19
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 and can give consent
- You have a recent confirmed COVID-19 test (RT-PCR)
- Your COVID-19 is “moderate” (low oxygen or breathing symptoms, not the mildest form)
- You are not in severe shock/unstable blood pressure (as judged by the study team)
- If you can become pregnant, you agree to strong birth control during and for 30 days after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.